Kyverna Therapeutics Stock Discussion

$Kyverna Therapeutics (KYTX.US)$
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Kyverna Therapeutics presented updated clinical data for KYV-101, their CD19 CAR T-cell therapy for lupus nephritis (LN) treatment. The data shows sustained efficacy and durability in patients treated with the target dose of 1×108 CD19 CAR T cells, with four out of six patients having at least six months of fol...

$Kyverna Therapeutics (KYTX.US)$
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...